TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10467991
Drug: Partially vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially vegetable fat and protein-reduced milk (3.5 g fat/dl, 50% vegetable; 2.2 g protein/dl)
Study: 10467991
Drug: Full-vegetable-fat milk
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-vegetable-fat milk (3.5 g fat/dl, 100% vegetable; 3.0 g protein/dl)
Study: 2894993
Drug: WAL801 CL
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAL801 CL 8 mg b.d. for 15 days
Study: 27080209
Drug: E6005 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6005 ointment (0.2%)
Study: 20175714
Drug: Perindopril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril plus diuretic combination therapy
Study: 20175714
Drug: Perindopril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril monotherapy
Study: 17910536
Drug: Intervention programme
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention programme (15 weekly lessons of 1 hour each for 3 months)
Study: 10096374
Drug: finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: finasteride 5 mg daily
Study: 6282455
Drug: MACC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACC chemotherapy only (methotrexate, doxorubicin, cyclophosphamide, and lomustine)
Study: 26163437
Drug: Cisplatin-chemoradiotherapy (CRT)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-chemoradiotherapy (CRT) with weekly cisplatin (30 mg/m(2)/w)
Study: 26163437
Drug: Cetuximab-radiotherapy (ERT)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab-radiotherapy (ERT) with loading dose of 400 mg/m(2) followed by weekly doses of 250 mg/m(2)
Study: 19369376
Drug: High micronutrient
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High micronutrient treatment (100% RDA)
Study: 19369376
Drug: Low micronutrient
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low micronutrient treatment (15% RDA)
Study: 19369376
Drug: n-3 treatments
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 treatments (900 mg alpha-linolenic acid + 100 mg docosahexaenoic acid or 140 mg alpha-linolenic acid)
Study: 14762227
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg q.d. a.m.
Study: 14762227
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg q.d. p.m.
Study: 19269020
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg b.i.d.
Study: 11241051
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (0.074 mg/kg, subcutaneously, 3 times per week)
Study: 9152782
Drug: Captopril (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (37.5 mg daily)
Study: 675213
Drug: fenoterol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol (1.25 mg)
Study: 675213
Drug: reproterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: reproterol (2.5 mg)
Study: 675213
Drug: terbutaline (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline (2.5 mg)
Study: 675213
Drug: salbutamol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol (1.25 mg)
Study: 30945505
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with medication (Diclofenac Diethylamine Emulgel, 3 times a day for 2 weeks)
Study: 30945505
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Diclofenac Diethylamine Emulgel, 3 times a day for 2 weeks)
Study: 25935840
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 or 4 mg kg(‐1))
Study: 21546719
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (vitamin A, vitamin C, vitamin E)
Study: 17517850
Drug: Tafenoquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine (200 mg loading dose daily for 3 days, followed by 200 mg weekly for 6 months)
Study: 11549646
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 or 120 mg/d)
Study: 9542478
Drug: Zolmitriptan 15
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolmitriptan 15 mg
Study: 7864934
Drug: simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20 mg daily
Study: 3212150
Drug: Amitriptyline (37.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (37.5, 70 mg)
Study: 3212150
Drug: Trazodone (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (100, 200 mg)
Study: 3212150
Drug: Viloxazine (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine (100, 200 mg)
Study: 3212150
Drug: Protriptyline (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protriptyline (10, 20 mg)
Study: 27995519
Drug: Lanreotide 120
Normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 120 mg subcutaneously every 28 days
Study: 23340530
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency (PRF) at 42° C for 120 seconds, applied twice, once a week for 3 weeks.
Study: 21907499
Drug: Involuntary medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involuntary medication treatment
Study: 17127797
Drug: Ethanol dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol dose 1-2 ml (Group A)
Study: 17127797
Drug: Ethanol dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol dose >2 ml (Group B)
Study: 15262845
Drug: Sirolimus 3
Normalized name: temsirolimus 30 mg/3 mL (10 mg/mL) (first dilution) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 3 mg/d
Study: 15262845
Drug: Sirolimus 5
Normalized name: SIROLIMUS 5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [FYARRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 5 mg/d
Study: 30388182
Drug: Quit preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quit preparation module
Study: 22803422
Drug: Acupoint heat-sensitization
Normalized name: heather pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint heat-sensitization moxibustion (Group A), once daily for 4 weeks
Study: 22803422
Drug: Changtai Oral
Normalized name: CALCIUM 0.99 ORAL TABLET [HANTAI 8030 Ca-D3 GOLD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changtai Oral Liquid (Group B), 10 mL three times daily for 4 weeks
Study: 22803422
Drug: Changtai Oral
Normalized name: CALCIUM 0.99 ORAL TABLET [HANTAI 8030 Ca-D3 GOLD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changtai Oral Liquid (Group B)
Study: 12121581
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry tablets (taken twice daily)
Study: 12121581
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (250 ml three times daily)
Study: 12121581
Drug: Placebo (juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (juice + tablets)
Study: 19935757
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry tablets
Study: 12121581
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry tablets vs. cranberry juice
Study: 12121581
Drug: Both cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both cranberry juice and cranberry tablets
Study: 11226996
Drug: Metoclopramide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.25 mg/kg)
Study: 7899366
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg once-a-week (group A: n = 185)
Study: 7899366
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg once-a-month (group B: n = 176)
Study: 7899366
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg once-a-week (group A)
Study: 7899366
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg once-a-month (group B)
Study: 2526830
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and intracoronary streptokinase without immediate coronary angioplasty (Group I)
Study: 2526830
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and intracoronary streptokinase with immediate coronary angioplasty (Group II)
Study: 28501062
Drug: Systemic Propolis
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Propolis as an adjuvant to nonsurgical periodontal treatment
Study: 26153173
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg propranolol, 2 hours before surgery
Study: 26153173
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 15 mg ketamine and 50 µg fentanyl, 5 min before surgery
Study: 16368752
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (2 IU/m2)
Study: 9032099
Drug: Troglitazone 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 800 mg q.d.
Study: 22711185
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of EMLA
Study: 22711185
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac suppository
Study: 22711185
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of petrolatum ointment
Study: 15030456
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 3 g daily from engraftment to day 84
Study: 15030456
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir 5 mg/kg three times weekly from engraftment to day 84
Study: 11473677
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled corticosteroids (CS)
Study: 9433395
Drug: Urinary or
Normalized name: INVESTIGATIONAL ANTI-NEOPLASTIC DRUGS GENITOURINARY ORGANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary or recombinant human follicle stimulating hormone (FSH) treatment
Study: 26590950
Drug: Extended-release-plus-immediate-release bilayer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release-plus-immediate-release bilayer tablet (Test)
Study: 26590950
Drug: Gastro-resistant delayed-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant delayed-release tablet (Reference)
Study: 24980811
Drug: Moxifloxacin-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin-based triple therapy (MML): moxifloxacin 400 mg/day, metronidazole 500 mg b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Study: 24980811
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (AL-CML): amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. for the first 5 days, followed by clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for the second 5 days
Study: 24980811
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (CAL): amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days
Study: 21999231
Drug: CHO‐rFVIIa (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐rFVIIa (90 μg/kg for healthy subjects; 270 μg/kg for patients)
Study: 21999231
Drug: BHK‐rFVIIa (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHK‐rFVIIa (90 μg/kg for healthy subjects; 270 μg/kg for patients)
Study: 18672762
Drug: Compound Paeonol
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Paeonol Dripping Pill (CPDP)
Study: 18672762
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western therapy (Group A)
Study: 16896051
Drug: Vitamin/mineral combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin/mineral combination (factor A: retinol and zinc; factor B: riboflavin and niacin; factor C: ascorbic acid and molybdenum; factor D: beta-carotene, alpha-tocopherol, and selenium)
Study: 12795457
Drug: Omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole + Amoxicillin + Clarithromycin (OAC-L) for 1 week
Study: 12795457
Drug: Omeprazole +
Normalized name: Omeprazole + SyrSpend SF Alka
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole + Amoxicillin + Clarithromycin (OAC-H) for 1 week
Study: 11035891
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol administered 1 day after mifepristone
Study: 11035891
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol administered 2 days after mifepristone
Study: 11035891
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol administered 3 days after mifepristone
Study: 19156626
Drug: Acarbose (alpha-glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (alpha-glucosidase inhibitor)
Study: 8776746
Drug: Brofaromine (CGP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (CGP 11,305 A), a selective and reversible MAO A inhibitor
Study: 6376292
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate (TDB) tablet four times a day
Study: 6376292
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cimetidine (1.6 g daily)
Study: 6376292
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cimetidine after crossover
Study: 14556543
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg per day for 8 weeks
Study: 16923435
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n = 199) received optimized nonpharmacological and pharmacological cardiovascular treatments by a geriatrician according to guidelines.
Study: 24170758
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for adherence and depression (CBT-AD)
Study: 22038792
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg) once daily
Study: 20386475
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g arginine + 300 mg grape seed extract
Study: 20386475
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g arginine + 300 mg grape seed extract
Study: 15963082
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice daily plus famotidine 20 mg twice daily
Study: 12908901
Drug: Supplemental intakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental intakes of 0.3, 1.0 and 2.0 g EPA+DHA/d
Study: 12908901
Drug: Antioxidant co-supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant co-supplementation (200 microg Se, 3 mg Mn, 30 mg D-alpha-tocopheryl succinate, 90 mg ascorbic acid, 450 microg vitamin A)
Study: 1865542
Drug: E5 murine
Normalized name: Murine Ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5 murine monoclonal antibody (2 mg/kg)
Study: 31727667
Drug: Choosing Wisely
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choosing Wisely Australia 5 Questions resource and preparation video
Study: 31727667
Drug: Preparation video
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation video
Study: 23799810
Drug: Active reference
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active reference treatment
Study: 18437790
Drug: Immediate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate or early loaded implants
Study: 15134615
Drug: TNF-alpha inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha inhibitors (etanercept and infliximab)
Study: 15134615
Drug: No TNF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TNF-alpha inhibition therapy (Control Group 2)
Study: 12351257
Drug: 4% modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% modified gelatin (GEL)
Study: 12351257
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (RL)
Study: 9647031
Drug: Glutamine 4
Normalized name: glutamine 475 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine 4 g/day
Study: 9647031
Drug: Glutamine 8
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine 8 g/day
Study: 7807504
Drug: Quinapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10-40 mg twice daily) in Study I; titrated every 1-2 weeks for 6 weeks, followed by 6 weeks of therapy.
Study: 7807504
Drug: Quinapril (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (5-20 mg twice daily) in Study II; titrated every 4 weeks for 16 weeks, followed by a 12-week maintenance period.
Study: 790553
Drug: Ketoprofen 150
Normalized name: ketoprofen 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 150 mg daily
Study: 19318694
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 120 mg
Study: 16428050
Drug: Single-phase contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-phase contrast medium injection (Group 1)
Study: 16428050
Drug: Dual-phase contrast
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-phase contrast medium injection (Group 2)
Study: 16428050
Drug: Three-phase injection
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-phase injection (Group 3)
Study: 8884561
Drug: Diazoxide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (150 mg)
Study: 9532986
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg four times a day
Study: 30079863
Drug: Nicotine preloading
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine preloading with a 21 mg/24 hour nicotine patch for 4 weeks prior to quit date
Study: 27197192
Drug: Trastuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab and chemotherapy
Study: 22290743
Drug: Rivastigmine (4.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (4.6 mg/24 hours for 3 weeks)
Study: 19020639
Drug: Placebo (balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (balanced saline solution, 1 drop given preoperatively)
Study: 16363755
Drug: Transvaginal Sacrospinous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal Sacrospinous Uterine Suspension (SSUS)
Study: 8577211
Drug: Metformin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin after low protein breakfast
Study: 8577211
Drug: Metformin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin after low fat breakfast
Study: 8577211
Drug: Metformin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin after low carbohydrate breakfast
Study: 8577211
Drug: Metformin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin after standard breakfast
Study: 2251616
Drug: Bromocriptine (Parlodel;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (Parlodel; Sandoz) in doses up to 26 mg daily
Study: 2251616
Drug: Bromocriptine (Parlodel;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (Parlodel; Sandoz) in doses beyond 25-30 mg daily
Study: 2251616
Drug: Bromocriptine (Parlodel;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (Parlodel; Sandoz) with slow dose increases
Study: 425546
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no considerable treatment)
Study: 31575021
Drug: Oral Vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Vitamin A&D supplement (20,000 IU retinyl palmitate and 2000 IU cholecalciferol)
Study: 29878061
Drug: HMBF (0.81
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMBF (0.81 kcal/mL)
Study: 29878061
Drug: BMBF (0.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMBF (0.72 kcal/mL)
Study: 26881417
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with daily feedback
Study: 26881417
Drug: Lottery incentive
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lottery incentive (daily eligibility for approximately $1.40 if goal achieved)
Study: 26881417
Drug: Loss incentive
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss incentive ($42 allocated monthly upfront, $1.40 removed for each day the goal is not achieved)